Welcome to the Lilly Scientific Information Page for ECO/EASO 2026
European Congress on Obesity/ European Association for the Study of Obesity
Istanbul, Turkey
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
TUESDAY
- Disease State: Obesity
- Presented by: L J Aronne
- Molecule(s): Bimagrumab
Body Composition (DXA) Changes During 6-Month Withdrawal from Semaglutide and/or Bimagrumab Treatment of Adults with Obesity: The BELIEVE Study Extension
Trial(s) Overview:
WEDNESDAY
- Disease State: Obesity
- Presented by: L J Aronne, D B Horn, C Le Roux
- Molecule(s): Orforglipron
Orforglipron for the Maintenance of Body Weight Reduction Achieved with Injectable Therapy: ATTAIN MAINTAIN Trial
Trial(s) Overview:
WEDNESDAY
- Disease State: Obesity in Diabetes
- Presented by: L J Aronne, D B Horn, C Le Roux
- Molecule(s): Tirzepatide
SURMOUNT-MAINTAIN Trial: Tirzepatide for Maintenance of Body Weight Reduction
Trial(s) Overview:
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Georgios Dimitriadis
- Molecule(s): Tirzepatide
12-Month Weight Change With Tirzepatide vs. Semaglutide: A US Real-World Setting Study
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Theresa Hunter Gibble
- Molecule(s): Tirzepatide
Switching to Tirzepatide From a GLP1 RA Resulted in Weight Reduction: Results From 2 RealWorld Databases
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Theresa Hunter Gibble
- Molecule(s): Tirzepatide
12-Month Utilization Patterns of Tirzepatide in Adults With Obesity or Overweight: US Real-World Results
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Theresa Hunter Gibble
- Molecule(s): Tirzepatide
Tirzepatide Use Resulted in Weight Reduction Among GLP-1 RA-Naïve Individuals With Obesity: Results From 2 Real-World Studies
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Andreea Ciudin
- Molecule(s): Tirzepatide
ObEx program: Practical Educational Experience in SEEDO- and EASO-accredited Collaborating Centres for Obesity Management in Spain
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Obesity with No Diabetes
- Presented by: Sébastien Czernichow
- Molecule(s): Tirzepatide
Healthcare consumption and quality of life among people with obesity who are eligible for obesity management medication in France: results from the CONSTANCES cohort study
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obesity
- Presented by: Ximena Ramos Salas
- Molecule(s): Tirzepatide
Experiences and impact among children and adolescents living with obesity, and their caregivers: European results from a multinational cross-sectional survey (UNICORN)
Trial(s) Overview:
Real World Evidence
WEDNESDAY
- Disease State: Obstructive Sleep Apnea
- Presented by: Helene Vioix
- Molecule(s): Tirzepatide
Understanding the Clinical Complications and Healthcare Burden of OSA in Ex-US settings
Trial(s) Overview:
Real World Evidence
WEDNESDAY
WEDNESDAY
WEDNESDAY
THURSDAY
- Disease State: Obstructive Sleep Apnea
- Presented by: Jason Gordon
- Molecule(s): Tirzepatide
European Delphi Consensus to Inform Screening for Obstructive Sleep Apnoea (DISC-OSA) in People with Obesity: A Mixed-Methods Modified Delphi Study
Trial(s) Overview:
Real World Evidence
THURSDAY
- Disease State: Obesity with No Diabetes
- Presented by: Emily Wilkes
- Molecule(s): Tirzepatide
Life-Course Obesity Burden and Impact on Complications and Mortality: A Real-World Study
Trial(s) Overview:
Real World Evidence
THURSDAY
- Disease State: Obesity with No Diabetes
- Presented by: Ana Sanchez-Bao
- Molecule(s): Tirzepatide
Burden and Overlap of Obesity-Related Complications Across the BMI Spectrum: A Federated Analysis Across 5 European Databases
Trial(s) Overview:
Real World Evidence
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)